Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic Cancers - Episode 8

Standard Treatment Regimens for NRG1+ Pancreatic Cancer

June 14, 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses current standard therapeutics for patients with NRG1 fusion–positive pancreatic cancer.

EP. 1: Prevalence of NRG1 Fusions in Lung Cancer

EP. 2: Differences Between DNA and RNA Testing for NRG1

EP. 3: Standard Treatments for NRG1 Fusion+ NSCLC

EP. 4: Ongoing Research Efforts Targeting NRG1 in Lung Cancer

EP. 5: Efficacy With NRG1-Directed Agents in NSCLC

EP. 6: Prognosis, Rarity of NRG1+ Pancreatic Cancer

EP. 7: Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

Now Viewing

EP. 8: Standard Treatment Regimens for NRG1+ Pancreatic Cancer

EP. 9: Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

EP. 10: Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer

EP. 11: DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer

EP. 12: A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer

EP. 13: The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

EP. 14: Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

EP. 15: Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

EP. 16: The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors

EP. 17: The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer

EP. 18: Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer

EP. 19: Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors

EP. 20: NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers